Recurrent respiratory papillomatosis: an uncommon but potentially devastating effect of human papillomavirus in children
- PMID: 20606216
- DOI: 10.1258/ijsa.2010.010073
Recurrent respiratory papillomatosis: an uncommon but potentially devastating effect of human papillomavirus in children
Abstract
Human papillomavirus (HPV) causes disease not only in the genital tract, but also in the larynx. Within the larynx HPV 6/11 causes recurrent respiratory papillomatosis (RRP). RRP is relatively uncommon, yet it is devastating for the patient who requires many surgical procedures over years to control it. The cost of HPV-related genital tract disease is thought to be around pound31 million per annum, whereas RRP costs in the region of pound4 million annually despite RRP being comparatively rare. The HPV vaccination programme has brought great hope, although it is unfortunate that the current UK programme only targets high-risk HPV. Targeting both low- and high-risk HPV would have had additional benefits for the UK.
Similar articles
-
Epidemiology of recurrent respiratory papillomatosis.APMIS. 2010 Jun;118(6-7):450-4. doi: 10.1111/j.1600-0463.2010.02619.x. APMIS. 2010. PMID: 20553527 Review.
-
[Prevalence of human papilloma virus types and their influence on the course of the disease in children suffering from recurrent respiratory papillomatosis].Vestn Otorinolaringol. 2004;(3):29-33. Vestn Otorinolaringol. 2004. PMID: 15159735 Russian.
-
The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination.Vaccine. 2008 Aug 18;26(35):4513-8. doi: 10.1016/j.vaccine.2008.06.045. Epub 2008 Jul 1. Vaccine. 2008. PMID: 18598734
-
Identification of HPV DNA in patients with juvenile-onset recurrent respiratory papillomatosis using SYBR Green real-time PCR.Int J Pediatr Otorhinolaryngol. 2006 Mar;70(3):469-73. doi: 10.1016/j.ijporl.2005.07.018. Epub 2005 Aug 30. Int J Pediatr Otorhinolaryngol. 2006. PMID: 16137771
-
Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population.Laryngoscope. 2004 Nov;114(11 Pt 2 Suppl 104):1-23. doi: 10.1097/01.mlg.000148224.83491.0f. Laryngoscope. 2004. PMID: 15514560 Review.
Cited by
-
Advances in Recurrent Respiratory Papillomatosis Treatment: Adjuvant Intralesional Bevacizumab's Impact, Potential and Insights from a Case Series Study.Indian J Otolaryngol Head Neck Surg. 2024 Oct;76(5):3800-3806. doi: 10.1007/s12070-024-04612-z. Epub 2024 May 7. Indian J Otolaryngol Head Neck Surg. 2024. PMID: 39376305
-
Differences in Transcriptional Activity of Human Papillomavirus Type 6 Molecular Variants in Recurrent Respiratory Papillomatosis.PLoS One. 2015 Jul 7;10(7):e0132325. doi: 10.1371/journal.pone.0132325. eCollection 2015. PLoS One. 2015. PMID: 26151558 Free PMC article.
-
Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK.BMC Infect Dis. 2019 Jun 24;19(1):552. doi: 10.1186/s12879-019-4108-y. BMC Infect Dis. 2019. PMID: 31234784 Free PMC article.
-
Paediatric virology and human papillomaviruses: An update.Exp Ther Med. 2019 Jun;17(6):4337-4343. doi: 10.3892/etm.2019.7516. Epub 2019 Apr 22. Exp Ther Med. 2019. PMID: 31186676 Free PMC article.
-
A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France.Hum Vaccin Immunother. 2013 Apr;9(4):823-33. doi: 10.4161/hv.22994. Epub 2013 Apr 1. Hum Vaccin Immunother. 2013. PMID: 23563511 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources